Patents by Inventor F. Richard Bringhurst

F. Richard Bringhurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human parathyroid hormone modifications, preparation and use
    Patent number: 7479478
    Abstract: The present invention is related to synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28). Some of the peptides of the invention are at least 90% identical to a peptide consisting essentially of the amino acid sequence X01ValSerGluIleGlnLeuMetHis AsnLeuGlyLysHisLeuAsnSer MetX02ArgValGluTrpLeuArgLysLysLeu (SEQ ID NO:1), wherein X01 is Ser, Ala or Gly; and X02 is Glu or Arg.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: January 20, 2009
    Assignee: The General Hospital Corporation
    Inventors: F. Richard Bringhurst, Hisashi Takasu, Thomas J. Gardella, John T. Potts, Jr.
  • PTH analogs for renal osteodystrophy and related uses
    Patent number: 7270968
    Abstract: The invention relates to a mammalian cell lacking type-1 parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) receptor (PTH1R) activity and containing carboxyl-terminal parathyroid hormone receptor (CPTHR) activity. The invention also relates to a method of screening for agonists or antagonists for CPTHR.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: September 18, 2007
    Assignee: The General Hospital Corporation
    Inventors: F. Richard Bringhurst, Paola Divieti, Harald Jüppner
  • Screening assays for G protein coupled receptor agonists and antagonists
    Patent number: 7033773
    Abstract: Parathyroid hormone (PTH) and its closely related peptide, PTHrP, share the same receptor, PTHR. LLC-PK1 cells are porcine renal epithelial cells which do not normally express PTHR. The present-invention provides stably transfected LLC-PK1 cells which express human PTHR. Also provided are methods for determining whether a compound of interest is an agonist or antagonist of a Gs or Gq protein coupled receptor.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: April 25, 2006
    Assignee: The General Hospital Corporation
    Inventors: F. Richard Bringhurst, Hisashi Takasu
  • Human parathyroid hormone modifications, preparation and use
    Publication number: 20050203012
    Abstract: Synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28), comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula: (a) X01ValSerGluIleGlnLeuMetHisAsn (SEQ ID NO:1); LeuGlyLysHisLeuAsnSerMetX02Arg ValGluTrpLeuArgLysLysLeu (b) fragments thereof containing amino acids 1-24, 1-25, 1-26, or 1-27; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein: X01 is Ser, Ala or Gly; and X02 is Glu or Arg, provided that said peptide is not hPTH(1-26)NH2, hPTH(1-27)NH2 or hPTH(1-28)NH2.
    Type: Application
    Filed: October 7, 2004
    Publication date: September 15, 2005
    Applicant: The General Hospital Corporation
    Inventors: F. Richard Bringhurst, Hisashi Takasu, Thomas Gardella, John Potts
  • Nucleic acids encoding modified parathyroid hormone
    Patent number: 6803213
    Abstract: The present invention is related to a synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28). Some of the peptides of the invention are at least 90% identical to a peptide consisting essentially of the amino acid sequence X01ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMetX02ArgValGluTrpLeuArgLysLysLeu (SEQ ID NO:1), wherein X01 is Ser, Ala or Gly; and X02 is Glu or Arg.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: October 12, 2004
    Assignee: The General Hospital Corporation
    Inventors: F. Richard Bringhurst, Hisashi Takasu, Thomas J. Gardella, John T. Potts, Jr.
  • NUCLEIC ACIDS ENCODING MODIFIED PARATHYROID HORMONE
    Publication number: 20040176568
    Abstract: Synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28), comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
    Type: Application
    Filed: May 30, 2002
    Publication date: September 9, 2004
    Applicant: The General Hospital Corporation
    Inventors: F. Richard Bringhurst, Hisashi Takasu, Thomas J. Gardella, John T. Potts
  • Pth analogs for renal osteodystrophy and related uses
    Publication number: 20040014150
    Abstract: The invention relates to a mammalian cell lacking type-1 parathyroid hormone (PTH)/parathyroid hormone-related peptide(PTHrP)) receptor(PTH1R) activity and containing carboxyl-terminal parathyroid hormone receptor (CPTHR) activity. The invention also relates to a method of screening of agonists for antagonists for CPTHR.
    Type: Application
    Filed: July 8, 2003
    Publication date: January 22, 2004
    Inventors: F. Richard Bringhurst, Paola Divieti, Harald Juppner
  • Amino -terminal modified parathyroid hormone (PTH) analogs
    Publication number: 20030144209
    Abstract: PTH derivatives having one or more amino acid substitutions that confer PTH-1/PTH-2 receptor agonist properties comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
    Type: Application
    Filed: February 11, 2003
    Publication date: July 31, 2003
    Applicant: The Massachusetts Gerneral Hospital
    Inventors: F. Richard Bringhurst, Hisashi Takasu, Thomas J. Gardella
  • Amino-terminal modified parathyroid hormone (PTH) analogs
    Patent number: 6537965
    Abstract: Disclosed are novel parathyroid hormone (PTH) peptide derivatives. In particular, the invention relates to PTH derivatives having amino acid substitutions that confer PTH-1/PTH-2 receptor agonist or antagonist properties to the derivatives. Also disclosed are methods of preparing these novel derivatives, and methods of using these derivatives to treat mammalian conditions.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: March 25, 2003
    Assignee: The General Hospital Corporation
    Inventors: F. Richard Bringhurst, Hisashi Takasu, Thomas J. Gardella
  • Modified human parathyroid hormone
    Patent number: 6417333
    Abstract: The present invention is related to novel synthetic and/or recombinant biologically active peptide derivatives of parathyroid hormone (PTH). In particular, the invention relates to PTH derivatives of 28 amino acids or less, with one or more amino acid substitutions, methods of their preparation and use.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: July 9, 2002
    Assignee: The General Hospital Corporation
    Inventors: F. Richard Bringhurst, Hisashi Takasu, Thomas J. Gardella, John T. Potts, Jr.
  • Screening assays for G protein coupled receptor agonists and antagonists
    Patent number: 6183974
    Abstract: Parathyroid hormone (PTH) and its closely related peptide, PTHrP, share the same receptor, PTHR. LLC-PK1 cells are porcine renal epithelial cells which do not normally express PTHR. The present invention provides stably transfected LLC-PK1 cells which express human PTHR. Also provided are methods for determining whether a compound of interest is an agonist or antagonist of a Gs or Gq protein coupled receptor.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: February 6, 2001
    Assignee: The General Hospital Corporation
    Inventors: F. Richard Bringhurst, Hisashi Takasu